Using a special probe to take biopsies from lung nodules
Simultaneous CLE Guided Crybiopsy in Patients With Pulmonary Nodules
This study is testing a new way to take tissue samples from lung nodules using a special probe to see if it helps doctors better diagnose lung cancer in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University of Vienna Academic / other |
| Locations | 1 site (Vienna) |
| Trial ID | NCT06056882 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of simultaneous confocal laser endomicroscopy (CLE) guided cryobiopsy in patients with suspected lung carcinoma. It will include 20 patients, with 5 having suspected central airway invading lung carcinoma and 15 with suspected peripheral lung carcinoma, all requiring bronchoscopic histologic confirmation. The approach involves using a CLE probe to identify the target area and a cryoprobe to obtain tissue samples for analysis. The goal is to improve diagnostic accuracy and patient outcomes in lung cancer detection.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with a suspicion of lung carcinoma.
Not a fit: Patients with known allergies to fluorescin, those who are pregnant or lactating, or those unable to discontinue beta-blockers prior to the intervention may not benefit from this study.
Why it matters
Potential benefit: If successful, this method could enhance the accuracy of lung cancer diagnoses and lead to better treatment decisions.
How similar studies have performed: While this approach is innovative, similar studies using cryobiopsy techniques have shown promise in improving lung cancer diagnosis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \>18 years * Suspicion of lung carcinoma Exclusion Criteria: * Known allergy to fluorescin * Pregnancy and/or lactation * No discontinuation of ß-blocker 12 hours before intervention possible
Where this trial is running
Vienna
- Medical University of Vienna — Vienna, Austria (Recruiting)
Study contacts
- Principal investigator: Daniela Gompelmann — Medical University of Vienna
- Study coordinator: Daniela Gompelmann
- Email: daniela.gompelmann@meduniwien.ac.at
- Phone: 014040047730
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.